JAK Inhibitors for Alopecia Areata: Baricitinib, Ritlecitinib, and Deuruxolitinib Compared
Three JAK inhibitors are now FDA-approved for severe alopecia areata — more approvals for this condition than in the preceding 20 years. For people who have exhausted other options for significant AA, these drugs represent a genuine step change. Here's how they compare.
01Why JAK inhibitors for AA
Alopecia areata is an autoimmune condition — the immune system attacks hair follicles through a JAK-STAT inflammatory pathway. JAK inhibitors block this pathway, reducing the immune attack and allowing follicles to re-enter the growth phase. Unlike older treatments (steroid injections, topical minoxidil, contact sensitization), JAK inhibitors target the underlying immune mechanism rather than working around it.
02The three approved drugs compared
| Drug | Brand | Approval | Dose | Trial response rate |
|---|---|---|---|---|
| Baricitinib | Olumiant | June 2022 | 2–4mg daily | ~35–40% achieving ≥80% scalp coverage |
| Ritlecitinib | Litfulo | June 2023 | 50mg daily | ~30–35% achieving ≥80% coverage; approved for ages 12+ |
| Deuruxolitinib | Leqselvi | June 2024 | 8–12mg daily | ~40% achieving ≥90% coverage in trials |
JAK inhibitors are approved for alopecia areata — the autoimmune type. They have no evidence for androgenetic alopecia (pattern hair loss), which has a completely different mechanism. If you have AGA, these are not your drugs. If you have confirmed severe AA, this is now a relevant conversation with a dermatologist.
03The maintenance reality
AA typically returns when JAK inhibitor treatment stops — these are ongoing maintenance drugs, not a cure. The immune mechanism resumes when drug levels drop. Long-term use means long-term side effect monitoring: immune suppression risks, infection risk, and the class-level cardiovascular and malignancy labeling. This is a specialist-managed therapy, not a consumer-driven one.
First: confirm whether you have AA or AGA
Provider consult for hair loss type assessment
Paid link Start your plan →